Agile Therapeutics (AGRX) PT Raised to $8 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Agile Therapeutics (AGRX) Fair Value Target Raised to $9 at Janney
February 18, 2020 8:20 AM ESTJanney analyst Esther Hong raised the fair value target on Agile Therapeutics (NASDAQ: AGRX) to $9.00 (from $4.00) while maintaining a Buy rating after Twirla was approved.
The analyst commented, "AGRX announced FDA approval of Twirla, a weekly ethinyl estradiol and levonorgestrel contraceptive... More
